The combination of anti-PD-1 (pembrolizumab) and anti-PD-L1 (nivolumab) resulted in the augmented survival of patients with metastatic melanoma compared to patients treated with ipilimumab alone or chemotherapy alone [12,13,14]. The gene discussed is PDCD1; the disease is metastatic melanoma.